ACHIEVE LIFE SCIENCES, INC. Uncategorized Contracts & Agreements
52 Contracts & Agreements
- Open Market Sale AgreementSM, dated September 27, 2024, between Achieve Life Sciences, Inc. and Jefferies LLC (Filed With SEC on September 27, 2024)
- Contingent Convertible Debt Agreement, dated July 25, 2024, between Achieve Life Sciences, Inc., and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (Filed With SEC on July 29, 2024)
- ACHIEVE LIFE SCIENCES, INC. 1040 West Georgia Street, Suite 1030 Vancouver, BC V6E 4H1 (Filed With SEC on March 6, 2023)
- Letter of Variation, dated September 28, 2020, by and between Achieve Pharma UK Limited and Anthony Clarke (Filed With SEC on November 12, 2020)
- Letter of Variation, dated September 28, 2020, by and between Achieve Pharma UK Limited and Richard Stewart (Filed With SEC on November 12, 2020)
- Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 13, 2020)
- Form of Leak-out Agreement (Filed With SEC on December 16, 2019)
- At The Market Offering Agreement, dated June 7, 2019, by and between Achieve Life Sciences, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on June 7, 2019)
- CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on January 5, 2017)
- Lock-up Agreement (Filed With SEC on January 5, 2017)
- SUPPORT AGREEMENT (Filed With SEC on January 5, 2017)
- SUPPORT AGREEMENT (Filed With SEC on January 5, 2017)
- AGREEMENT BETWEEN ONCOGENEX TECHNOLOGIES, INC. (OGX) AND TEVA PHARMACEUTICAL INDUSTRIES LTD. (Teva) (Filed With SEC on March 26, 2015)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on November 3, 2011)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on November 3, 2011)
- /s/ Scott Cormack Scott Cormack, President & CEO (Filed With SEC on November 8, 2010)
- OncoGenex Pharmaceuticals, Inc. (Filed With SEC on October 19, 2010)
- a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer (CRPC), expected to initiate in the second quater of 2010... (Filed With SEC on March 8, 2010)
- a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer (CRPC), expected to initiate in the second quater of 2010... (Filed With SEC on March 8, 2010)
- a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer (CRPC), expected to initiate in the second quater of 2010... (Filed With SEC on March 8, 2010)
- a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer (CRPC), expected to initiate in the second quater of 2010... (Filed With SEC on March 8, 2010)
- OncoGenexTechnologies Inc. is a wholly owned subsidiary of OncoGenexPharmaceuticals, Inc. NASD- OGXI www.oncogenex.com (Filed With SEC on February 25, 2010)
- Consolidated Financial Statements (Filed With SEC on November 5, 2009)
- Consolidated Financial Statements (Filed With SEC on November 5, 2009)
- Consolidated Financial Statements (Filed With SEC on November 5, 2009)
- Agreement and Consent Form (Filed With SEC on April 2, 2009)
- longer survival duration when adding OGX-011 to first-line docetaxel compared to first-line docetaxel alone in patients with CRPC within a randomized phase 2 trial (Filed With SEC on March 11, 2009)
- SECOND AMENDING AGREEMENT (Filed With SEC on November 10, 2008)
- SECOND AMENDING AGREEMENT AND CONSENT (Filed With SEC on November 10, 2008)
- SECOND AMENDMENT TO ARRANGEMENT AGREEMENT (Filed With SEC on November 10, 2008)
- FIRST AMENDMENT TO ARRANGEMENT AGREEMENT (Filed With SEC on November 10, 2008)
- THIRDAMENDMENT TO AMENDED AND RESTATED RIGHTS AGREEMENT (Filed With SEC on May 30, 2008)
- SONUS PHARMACEUTICALS, INC. 1522 217th PL S.E., Suite 100 Bothell, Washington 98021 January 11, 2008 (Filed With SEC on January 17, 2008)
- SonusPharmaceuticals, Inc. ExecutiveCompensation Program (Filed With SEC on December 15, 2006)
- SonusPharmaceuticals, Inc. CompensationPolicy (Filed With SEC on December 15, 2006)
- Amendedand Restated Sonus Pharmaceuticals, Inc. ExecutiveCompensation Program (Filed With SEC on January 4, 2005)
- EXHIBIT A FORM OF STOCKHOLDERS AGREEMENT (Filed With SEC on December 28, 2004)
- TOCOSOL Drug Delivery Technology (Filed With SEC on March 12, 2004)
- TOCOSOL Drug Delivery Technology (Filed With SEC on March 12, 2004)
- TOCOSOL Drug Delivery Technology (Filed With SEC on March 12, 2004)
